4.3 Article

Induction of DISE in ovarian cancer cells in vivo

Journal

ONCOTARGET
Volume 8, Issue 49, Pages 84643-84658

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.21471

Keywords

RNAi; Fas; ovarian cancer; TLP nanoparticles; cell death

Funding

  1. CCNE [U54 CA151880, R35CA197450]
  2. Friends of Prentice grant
  3. Department of Defense/Air Force Office of Scientific Research [FA95501310192]
  4. National Institutes of Health/National Cancer Institute [R01CA167041]
  5. Ryan Family
  6. Malkin Family
  7. Driskill Family
  8. Chicago Baseball Charities Cancer Fellowship
  9. Northwestern University Feinberg School of Medicine Developmental Therapeutic Institute
  10. [T32CA070085]
  11. [T32CA009560]

Ask authors/readers for more resources

The death receptor CD95/Fas can be activated by immune cells to kill cancer cells. shRNAs and siRNAs derived from CD95 or CD95 ligand (CD95L) are highly toxic to most cancer cells. We recently found that these sh/siRNAs kill cancer cells in the absence of the target by targeting the 3'UTRs of critical survival genes through canonical RNAi. We have named this unique form of off-target effect DISE (for death induced by survival gene elimination). DISE preferentially kills transformed cells and cancer stem cells. We demonstrate that DISE induction occurs in cancer cells in vivo after introducing a lentiviral CD95L derived shRNA (shL3) into HeyA8 ovarian cancer cells grown as i.p. xenografts in mice, when compared to a scrambled shRNA. To demonstrate the possibility of therapeutically inducing DISE, we coupled siRNAs to templated lipoprotein nanoparticles (TLP). In vitro, TLPs loaded with a CD95L derived siRNA (siL3) selectively silenced a biosensor comprised of Venus and CD95L ORF and killed ovarian cancer cells. In vivo, two siRNA-TLPs (siL2-TLP and siL3-TLP) reduced tumor growth similarly as observed for cells expressing the shL3 vector. These data suggest that it is possible to kill ovarian cancer cells in vivo via DISE induction using siRNA-TLPs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available